Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Effect of Subcutaneous Methoxy Polyethylene Glycol-epoetin Beta on Anemia and Nutritional Indices in Peritoneal Dialysis Patients

복막투석 환자에서 Methoxy Polyethylene Glycol-epoetin Beta 피하 투여가 빈혈과 영양지표에 미치는 효과

  • Kim, Kyung Sook (College of Pharmacy, Chungbuk National University) ;
  • Lee, Jun Seop (Department of Pharmacy, Chungbuk National University Hospital) ;
  • Kim, Hye-Young (Department of Internal Medicine, College of Medicine, Chungbuk National University) ;
  • Lee, Myung Koo (College of Pharmacy, Chungbuk National University)
  • 김경숙 (충북대학교 약학대학) ;
  • 이준섭 (충북대학교병원 약제부) ;
  • 김혜영 (충북대학교 의과대학 내과학교실) ;
  • 이명구 (충북대학교 약학대학)
  • Received : 2012.07.11
  • Accepted : 2012.08.15
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Methoxy polyethylene glycol-epoetin beta (MPG-EPO), a continuous erythropoietin receptor activator, is a new erythropoiesis-stimulating agent with a long half-life. The purpose of this prospective study is to assess the effects of once-monthly subcutaneous MPG-EPO on hematological responses and nutritional status in peritoneal dialysis patients. Forty four patients undergoing stable peritoneal dialysis were enrolled into the study. Darbepoetin alfa therapy, in peritoneal dialysis patients, was converted to the monthly administration of subcutaneous MPG-EPO for 6 months. The starting dose of MPG-EPO was based on the previous weekly dose of darbepoetin alfa. The dose adjustments were performed to maintain the hemoglobin (Hb) levels in a target range of 10.5-11.0 g/dL. If the Hb levels exceeded 11.0 g/dL, MPG-EPO was temporarily interrupted for 1 month. The mean Hb levels were stable with the values of $9.5{\pm}1.1$ g/dL at baseline, and $10.4{\pm}0.9$ g/dL at the 6th month after conversion. The mean differences in the changes of Hb levels between the baseline and the 6th month were $0.9{\pm}1.4$ g/dL, which was statistically significant. However, the mean differences of iron, transferrin saturation and ferritin concentrations were not significant. It did not show significant differences in the changes of the nutritional parameters. These results suggest that the once-monthly subcutaneous administration of MPG-EPO for 6 months effectively maintains the Hb levels and nutritional status in peritoneal dialysis patients. Taken together, the once-monthly subcutaneous administration of MPG-EPO was practical and might improve the clinical compliance for the management of renal anemia in peritoneal dialysis patients.

Keywords

References

  1. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65(5): 1864-9. https://doi.org/10.1111/j.1523-1755.2004.00584.x
  2. 안승찬, 최승옥, 신승준, 등. 혈액투석중인 만성신부전 환자의 빈혈에 관한 연구. 대한신장학회지 1994; 13(4): 769-775.
  3. 임춘수. 만성 신질환 환자에서 빈혈의 치료. 대한신장학회지 2006; 25(2): S551-S558.
  4. Eschbach JW, Egrie JC, Downing MR, et al., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316(2): 73-78. https://doi.org/10.1056/NEJM198701083160203
  5. Winearls CG, Oliver DO, Pippard MJ, et al., Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 1986; 2(8517): 1175-1178.
  6. Nicoletta P, Bernardini J, Dacko C, et al., Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 90-92.
  7. Nissenson AR, Swan SK, Lindberg JS, et al., Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40(1): 110-118. https://doi.org/10.1053/ajkd.2002.33919
  8. Locatelli F, Canaud B, Giacardy F, et al., Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18(2): 362-369. https://doi.org/10.1093/ndt/18.2.362
  9. Curran MP, McCormack PL. Methoxy polyethylene glycolepoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008; 68(8): 1139-1156. https://doi.org/10.2165/00003495-200868080-00009
  10. Jarsch M, Brandt M, Lanzendorfer M, et al., Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacol 2008: 81(1): 63-69. https://doi.org/10.1159/000109166
  11. Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (continuous erythropoietin receptor activator). Int J Nanomed 2007; 2(1): 33-38. https://doi.org/10.2147/nano.2007.2.1.33
  12. Fouque D, Pelletier S, Mafra D, et al., Nutrition and chronic kidney disease. Kidney Int 2011; 80(4): 348-357. https://doi.org/10.1038/ki.2011.118
  13. McCarthy JT. A practical approach to the management of patients with chronic renal failure. Mayo Clin Proc 1999; 74(3): 269-273. https://doi.org/10.4065/74.3.269
  14. 강재영, 정두련, 김경조, 등. r-HuEPO 투여후 복막투석 환자의 영양지표의 변화에 대한 연구. 대한신장학회지 1995; 14(2): 205-212.
  15. Tarng DC, Huang TP, Doong TI. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron 1998; 78(3): 253-259. https://doi.org/10.1159/000044931
  16. Gandra SR, Finkelstein FO, Bennett AV, et al., Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 2010; 55(3): 519-534. https://doi.org/10.1053/j.ajkd.2009.09.019
  17. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300(6724): 573-578. https://doi.org/10.1136/bmj.300.6724.573
  18. Klinger M, Arias M, Vargemezis V, et al., Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50(6): 989-1000. https://doi.org/10.1053/j.ajkd.2007.08.013
  19. Canaud B, Mingardi G, Braun J, et al., Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23(11): 3654-3661. https://doi.org/10.1093/ndt/gfn320
  20. Levin NW, Fishbane S, Canedo FV, et al., Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370(9596): 1415-1421. https://doi.org/10.1016/S0140-6736(07)61599-2
  21. Locatelli F, Villa G, de Francisco AL, et al., Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23(5): 969-979. https://doi.org/10.1185/030079907X182103
  22. Sulowicz W, Locatelli F, Ryckelynck JP, et al., Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2(4): 637-646. https://doi.org/10.2215/CJN.03631006
  23. Macdougall IC, Walker R, Provenzano R, et al., C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3(2): 337-347. https://doi.org/10.2215/CJN.00480107
  24. Kessler M, Martinez-Castelao A, Siamopoulos KC, et al., C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int 2010; 14(2): 233-239. https://doi.org/10.1111/j.1542-4758.2009.00421.x
  25. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5): S16-S85. https://doi.org/10.1053/j.ajkd.2006.03.011
  26. Astor BC, Muntner P, Levin A, et al., Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162(12): 1401-1408. https://doi.org/10.1001/archinte.162.12.1401
  27. 신승희, 지은희, 이영숙, 등. 혈액투석 환자의 빈혈관리에서 erythropoietin 반응에 영향을 미치는 인자. 한국임상약학회지 2011; 21(2): 122-130.
  28. 이윤덕, 김경임, 김영주, 등. 항암치료로 인한 빈혈의 치료에서 Epoetin Alpha 주일회요법과 주삼회요법의 약효 비교 연구. 한국임상약학회지 2009; 19(2): 146-152.
  29. Snyder JJ, Foley RN, Gibertson DT, et al., Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15(1): 174-179 https://doi.org/10.1097/01.ASN.0000102475.94185.54
  30. Carrera F, Lok CE, de Francisco A, et al., Maintenance treatment of renal anemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25(12): 4009-4017. https://doi.org/10.1093/ndt/gfq305
  31. Roger SD, Locatelli F, Woitas RP, et al., C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant, 2011; 26(12): 3980-3986. https://doi.org/10.1093/ndt/gfr160
  32. Grzegorzewska AE, Leander M. Lymphocyte subset counts in continuous ambulatary peritoneal dialysis patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors. Adv Perit Dial 2002; 18: 6-11.
  33. Paskalev E. Influence of anemia treatment of malnutrition in patirnts on hemodialysis. Nephron 2000; 86(2): 215-216. https://doi.org/10.1159/000045755
  34. 서정철, 김혜영, 양용모, 등. 혈액투석 환자에서 erythropoietin 의 피하주사와 저용량 androgen의 병용투여가 빈혈과 영양지표에 미치는 효과. 대한신장학회지 2001; 20(1): 67-74.
  35. NKF-KDOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35(6): S17- S104. https://doi.org/10.1053/ajkd.2000.v35.aajkd03517